An Open-Label, Multi-Center, Single-Arm Study to Evaluate the Efficacy of Nilotinib in Adult Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line Treatment
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 01 Jun 2018
At a glance
- Drugs Nilotinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 17 Apr 2018 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
- 17 Apr 2018 Planned primary completion date changed from 30 Apr 2018 to 31 Dec 2019.
- 27 Mar 2018 Planned End Date changed from 31 Dec 2017 to 31 Dec 2018.